

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Initial Patent Application of

Atty Dkt. 2551-117

C# M#

MAERTENS et al.

AUG 25 2003

Group Art Unit: 1631

Serial No. 09/873,224

Examiner: Martinell

Filed: June 5, 2001

Date: August 25, 2003

Title: NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS THERAPEUTIC

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☒ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment	34	minus highest number			
previously paid for	34	(at least 20) =	0	x	\$ 18.00
					\$ 0.00
Independent claims after amendment	2	minus highest number			
previously paid for	4	(at least 3) =	0	x	\$ 84.00
					\$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)

\$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months)

\$ 110.00

Terminal disclaimer enclosed, add \$ 110.00

\$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00)

\$ 0.00

☐ Please enter the previously unentered, filed☐ Submission attached**Subtotal \$ 110.00**

If "small entity," then enter half (1/2) of subtotal and subtract

-\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)

\$ 180.00

Assignment Recording Fee (\$40.00)

\$ 0.00

Other: Copy of Notification of Acceptance (2/10/95) received in 08/362,455; Amendment and copies of (8) documents referenced to in Amendment; Information Disclosure Statement; PTO-1449 Form; Copies of (5) Cited References; Statement; Paper and Computer Readable Copies of Sequence Listing

0.00

**TOTAL FEE ENCLOSED \$ 290.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:plb

NIXON & VANDERHUYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

09/08/2003 03:00:00 00000002 09873224

110.00 09

09/08/2003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2551-117


C# M#

MAERTENS et al.

Serial No. 09/873,224

Filed: June 5, 2001

Title: NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS THERAPEUTIC



Group Art Unit: 1631

Examiner: Martinell

Date: August 25, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
AUG 29 2003  
TECH CENTER 1600/2900

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☒ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment **34** minus highest number  
previously paid for **34** (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment **2** minus highest number  
previously paid for **4** (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months) \$ 110.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

**Subtotal** \$ 110.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 180.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: Copy of Notification of Acceptance (2/10/95) received in 08/362,455; Amendment and copies of (8) documents referenced to in Amendment; Information Disclosure Statement; PTO-1449 Form; Copies of (5) Cited References; Statement; Paper and Computer Readable Copies of Sequence Listing' 0.00

**TOTAL FEE ENCLOSED** \$ 290.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:plb

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: \_\_\_\_\_



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS et al.

Serial No. 09/873,224

Filed: June 5, 2001

Atty. Ref.: 2551

Group: 1631

Examiner: Martinell

For: NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS  
THERAPEUTIC AND DIAGNOSTIC AGENTS

\* \* \* \* \*

August 25, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT**

Responsive to the Office Action dated April 25, 2003, entry and consideration of the following amendments and remarks are requested; the period for response having been extended up to and including August 25, 2003, by submission of the requisite petition and fee, attached